David J Pinato1, Anu Vallipuram2, Joanne S Evans2, Clement Wong2, Hua Zhang3, Matthew Brown2, Roberto E Dina4, Pritesh Trivedi4, Ayse U Akarca5, Teresa Marafioti5, Francesco A Mauri2, Rohini Sharma2. 1. Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, United Kingdom, david.pinato@imperial.ac.uk. 2. Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, United Kingdom. 3. Department of Medical Oncology, LC-4112, Dana-Farber Cancer Institute, Boston, Massachusetts, USA. 4. Department of Histopathology, Imperial College London, Hammersmith Hospital, London, United Kingdom. 5. Department of Histopathology, Rockefeller Building, University College London Hospital, London, United Kingdom.
Abstract
INTRODUCTION: A comprehensive characterization of the tumour microenvironment is lacking in neuroendocrine tumours (NETs), where programmed cell death-1 receptor-ligand (PD-1/PD-L1) inhibitors are undergoing efficacy testing. OBJECTIVE: We investigated drivers of cancer-related immunosuppression across NETs of various sites and grades using multi-parameter immunohistochemistry and targeted transcriptomic profiling. METHODS: Tissue microarrays (n = 102) were stained for PD-L1 and 2 and indoleamine deoxygenase-1 (IDO-1) and evaluated in relationship to functional characteristics of tumour-infiltrating T-lymphocytes (TILs) and biomarkers of hypoxia/angiogenesis. PD-L1 expression was tested in circulating tumour cells (CTCs, n = 12) to evaluate its relationship with metastatic dissemination. RESULTS: PD-L1 expression was highest in lung NETs (n = 30, p = 0.007), whereas PD-L2 was highest in pancreatic NETs (n = 53, p < 0.001) with no correlation with grade or hypoxia/angiogenesis. PD-L1+ NETs (n = 26, 25%) had greater CD4+/FOXP3+ and CD8+/PD1+ TILs (p < 0.001) and necrosis (p = 0.02). CD4+/FOXP3+ infiltrate had the highest PD-L1/IDO-1 co-expressing tumours (p = 0.006). Grade 3 well-differentiated NETs had lower CD4+/FOXP3+ and CD8+/PD1+ TIL density (p < 0.001), and NanoString immune profiling revealed enrichment of macrophage-related transcripts in cases with poorer prognosis. We identified PD-L1(+) CTC subpopulations in 75% of evaluated patients (n = 12). CONCLUSIONS: PD-L1 expression correlates with T-cell exhaustion independent of tumour hypoxia and is enhanced in a subpopulation of CTCs, suggesting its relevance to the progression of NETs. These findings support a potential therapeutic role for PD-L1 inhibitors in a subset of NETs.
INTRODUCTION: A comprehensive characterization of the tumour microenvironment is lacking in neuroendocrine tumours (NETs), where programmed cell death-1 receptor-ligand (PD-1/PD-L1) inhibitors are undergoing efficacy testing. OBJECTIVE: We investigated drivers of cancer-related immunosuppression across NETs of various sites and grades using multi-parameter immunohistochemistry and targeted transcriptomic profiling. METHODS: Tissue microarrays (n = 102) were stained for PD-L1 and 2 and indoleamine deoxygenase-1 (IDO-1) and evaluated in relationship to functional characteristics of tumour-infiltrating T-lymphocytes (TILs) and biomarkers of hypoxia/angiogenesis. PD-L1 expression was tested in circulating tumour cells (CTCs, n = 12) to evaluate its relationship with metastatic dissemination. RESULTS:PD-L1 expression was highest in lung NETs (n = 30, p = 0.007), whereas PD-L2 was highest in pancreatic NETs (n = 53, p < 0.001) with no correlation with grade or hypoxia/angiogenesis. PD-L1+ NETs (n = 26, 25%) had greater CD4+/FOXP3+ and CD8+/PD1+ TILs (p < 0.001) and necrosis (p = 0.02). CD4+/FOXP3+ infiltrate had the highest PD-L1/IDO-1 co-expressing tumours (p = 0.006). Grade 3 well-differentiated NETs had lower CD4+/FOXP3+ and CD8+/PD1+ TIL density (p < 0.001), and NanoString immune profiling revealed enrichment of macrophage-related transcripts in cases with poorer prognosis. We identified PD-L1(+) CTC subpopulations in 75% of evaluated patients (n = 12). CONCLUSIONS:PD-L1 expression correlates with T-cell exhaustion independent of tumour hypoxia and is enhanced in a subpopulation of CTCs, suggesting its relevance to the progression of NETs. These findings support a potential therapeutic role for PD-L1 inhibitors in a subset of NETs.
Authors: Petros Fessas; Paolo Spina; Renzo L Boldorini; Mario Pirisi; Rosalba Minisini; Francesco A Mauri; Fraser Simpson; Paola Olivieri; Alessandra Gennari; Ching Ngar Wong; Abdul Siddique; Robert D Goldin; Ayse U Akarca; Teresa Marafioti; David J Pinato Journal: Cancers (Basel) Date: 2021-04-29 Impact factor: 6.639
Authors: Marina Natoli; John Gallon; Haonan Lu; Ala Amgheib; David J Pinato; Francesco A Mauri; Teresa Marafioti; Ayse U Akarca; Ines Ullmo; Jacey Ip; Eric O Aboagye; Robert Brown; Anastasios Karadimitris; Sadaf Ghaem-Maghami Journal: J Immunother Cancer Date: 2021-01 Impact factor: 13.751
Authors: Mario Orozco-Morales; Alejandro Avilés-Salas; Norma Hernández-Pedro; Rodrigo Catalán; Graciela Cruz-Rico; Ana Laura Colín-González; Elsa Dosal-Mancilla; Pedro Barrios-Bernal; Oscar Arrieta Journal: J Immunol Res Date: 2021-06-11 Impact factor: 4.818
Authors: David J Pinato; Sam M Murray; Alejandro Forner; Takahiro Kaneko; Petros Fessas; Pierluigi Toniutto; Beatriz Mínguez; Valentina Cacciato; Claudio Avellini; Alba Diaz; Rosemary J Boyton; Daniel M Altmann; Robert D Goldin; Ayse U Akarca; Teresa Marafioti; Francesco A Mauri; Edoardo Casagrande; Federica Grillo; Edoardo Giannini; Sherrie Bhoori; Vincenzo Mazzaferro Journal: J Immunother Cancer Date: 2021-09 Impact factor: 13.751